Direct and indirect costs of pain therapy for osteoarthritis in an insured population in the United States.
about
Associations between MRI features versus knee pain severity and progression: Data from the Vancouver Longitudinal Study of Early Knee OsteoarthritisEconomic and Humanistic Burden of Osteoarthritis: A Systematic Review of Large Sample Studies.Effect of bisphosphonate use in patients with symptomatic and radiographic knee osteoarthritis: data from the Osteoarthritis Initiative.Evaluating the health and economic impact of osteoarthritis pain in the workforce: results from the National Health and Wellness SurveyCosts of moderate to severe chronic pain in primary care patients - a study of the ACCORD ProgramRelationship between patient-reported disease severity in osteoarthritis and self-reported pain, function and work productivity.Impact of self-rated osteoarthritis severity in an employed population: cross-sectional analysis of data from the national health and wellness survey.Does moderate or severe nonspecific knee injury affect radiographic osteoarthritis incidence and progression?Burden of restraint, disablement, and ethnic identity: a case study of total joint replacement for osteoarthritis.Lifetime medical costs of knee osteoarthritis management in the United States: impact of extending indications for total knee arthroplasty.Health care costs in US patients with and without a diagnosis of osteoarthritisA Mechanism-Based Approach to the Management of Osteoarthritis PainPatterns of intra-articular injection use after initiation of treatment in patients with knee osteoarthritis: data from the osteoarthritis initiative.Well-being among older adults with OA: direct and mediated patterns of control beliefs, optimism and pessimism.Studies of pain management in osteoarthritis: bedside to policy.Healthcare costs associated with osteoarthritis in US patients.Economic outcomes for celecoxib: a systematic review of pharmacoeconomic studies.The impact of ethnicity and cardiovascular risk on the pharmacologic management of osteoarthritis: a US perspective.Emerging drugs for the treatment of knee osteoarthritis.Cost of arthritis: a systematic review of methodologies used for direct costs.Duration of symptom relief after intra-articular injection of hyaluronic acid combined with sorbitol (anti-ox-vs) in symptomatic hip osteoarthritis.Therapy switching, augmentation, and discontinuation in patients with osteoarthritis and chronic low back pain.The excess burden of osteoarthritis in the province of Ontario, Canada.Cost Burden of Chronic Pain Patients in a Large Integrated Delivery System in the United States.Use and costs of prescription medications and alternative treatments in patients with osteoarthritis and chronic low back pain in community-based settings.Cost-effectiveness of total knee replacement: a prospective cohort study.Healthcare resource utilization and costs by age and joint location among osteoarthritis patients in a privately insured population.Osteoarthritis in Europe: impact on health status, work productivity and use of pharmacotherapies in five European countries.Systematic clinical evidence review of NASHA (Durolane hyaluronic acid) for the treatment of knee osteoarthritis.
P2860
Q30000302-CD31EB08-68E1-4D0D-B57C-CCA5E14CAD67Q30244295-7ECFE2D4-6F9B-44F3-9461-C36E382F4D6DQ30616581-EA813118-5749-437C-9429-0D821D4CF692Q33884111-8289EE8D-8942-4575-BD3A-45686CCFA33FQ33890193-606A75AF-B77B-4F2E-A8DC-14FE5C85C4BCQ34153131-778D8EA6-D7A4-44F2-936C-50AD7BE5D521Q34196818-E320832D-0463-469E-8780-EF8FAA6E8C34Q34508378-D0A1F742-1F32-4B54-B13E-71FA94C720DAQ35117164-140BD786-FC77-4EFF-887F-2B1C4B38AC94Q35576022-8451E13C-06A6-4743-972B-7636071BF221Q35739651-D76E40FF-8435-45A5-A8DE-EE61557D6351Q36217637-C16E231E-606C-47A0-BA21-5A5D08632476Q36408870-A6997288-5439-4547-9268-B8F825CBA282Q36961535-02837C9B-C898-456D-9B98-1FB3DEC0A4CEQ37454978-399F39B1-F9A4-44F1-BD61-203616032F4FQ37981710-48B33C18-9629-4A6D-B6BD-AC594E0A698FQ38042714-518F7B0D-CE05-4889-9DE1-70720C1D1468Q38316845-36619BFC-B211-41C3-9369-85B7F42F31B1Q38417521-311DBBA1-0BB2-47C4-917A-3B46BF1D8BCCQ38652998-B0DD1767-B7A1-4C94-B50D-2DF40830FDDDQ39204285-7DFCA96E-1599-4CEC-83F6-8D140696EFE6Q39253569-BDA8E65F-AF82-4EBF-99D0-11C3346AD065Q40007318-A7776213-7374-4A02-ACEC-320F8DF5A64FQ40459480-3B606842-FB89-41BF-93A5-349314EC911EQ45748116-0873BAAA-3C4F-4FF3-8733-3FB9039F0015Q45833487-E88C10E9-A69E-4812-B045-DE2CAD1CD220Q47648490-F4311C9B-54A9-4BC2-AD33-E3523D615ACCQ48359637-C1629F33-77C8-4F62-AFDD-3C9ED02E1720Q55187942-A04D4758-5B5B-4983-B489-B873392ACBEF
P2860
Direct and indirect costs of pain therapy for osteoarthritis in an insured population in the United States.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Direct and indirect costs of p ...... pulation in the United States.
@en
Direct and indirect costs of p ...... pulation in the United States.
@nl
type
label
Direct and indirect costs of p ...... pulation in the United States.
@en
Direct and indirect costs of p ...... pulation in the United States.
@nl
prefLabel
Direct and indirect costs of p ...... pulation in the United States.
@en
Direct and indirect costs of p ...... pulation in the United States.
@nl
P2093
P1476
Direct and indirect costs of p ...... pulation in the United States.
@en
P2093
Alan G White
Carmela Janagap
Howard G Birnbaum
Jeff Schein
Sharon Buteau
P304
P356
10.1097/JOM.0B013E3181715111
P407
P577
2008-09-01T00:00:00Z